Important information

Publication or distribution of information from this section of Curasight A/S’s (“Curasight” or the “Company”) website may in some jurisdictions be subject to restrictions by law and persons in the jurisdictions where information from this section of Curasight’s website has been published or distributed should inform themselves of and comply with such legal restrictions. The recipient of information from this section of Curasight’s website is responsible for using this information from this section of Curasight’s website and the information contained herein in accordance with the applicable regulations of the respective jurisdiction. This information from this section of Curasight’s website does not constitute an offer to, or an invitation to, acquire or subscribe for any securities of the Company in any jurisdiction, either from the Company or from anyone else, other than as disclosed in the Company’s prospectus approved by the Danish Financial Supervisory Authority in accordance with Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and the “Prospectus”.

This information from this section of Curasight’s website neither identifies nor purports to identify risks (direct or indirect) that may be attributable to an investment in any securities issued by the Curasight. An investment decision the must be made on the basis of all publicly available information regarding the Company and the Company's securities including the Prospectus. The information from this section of Curasight’s website is published as background information only and does not claim to be complete. Accordingly, an investor should not rely solely on the information from this section of Curasight’s website or its accuracy or completeness.

This information from this section of Curasight’s website does not constitute a recommendation for any investors' decisions regarding the offer of units by the Company. Each investor or potential investor should conduct its own investigation, analysis and evaluation of the business and information described in Prospectus. The price and value of any securities issued by the Company may decrease as well as increase. Achieved results do not constitute a guide for future results.

This information from this section of Curasigh’ts website does not constitute an offer or invitation to acquire or subscribe for the Company’s securities in the United States. The securities referred to herein may not be sold in the United States without registration, or without application of an exemption from registration, under the then-current U.S. Securities Act of 1933 ("Securities Act") and may not be offered or sold in the United States without being registered, subject to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act. There is no intention to register any securities mentioned herein in the United States or to make a public offering of such securities in the United States. The information from this section of Curasight’s website may not be published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or to United States, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, Belarus or Russia or any other jurisdiction where such publication , publication or distribution of this information would be contrary to current regulations or where such an action is subject to legal restrictions or would require additional registration or other measures than what follows from Danish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.

Save for the Prospectus itself, the information from this section of Curasight’s website is not a prospectus within the meaning of the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. The Company has not approved any offer to the public of shares, units or rights in any member state of the EEA and no prospectus has been drawn up or will be drawn up in connection with the Company’s offer of units. In each EEA Member State, this notice is directed only to "eligible investors" in that Member State as defined in the Prospectus Regulation.

The Prospectus has been passported to Sweden in accordance with article 25 of the Prospectus Regulation.

The shares, units or warrants, as the case may be, in the Company are not subject to trading or application in any country other than Denmark and Sweden. Invitation according to the Prospectus is not addressed to persons whose participation presupposes the publication or approval of additional Prospectuses, registration measures or other measures than those that comply with Danish law. The Prospectus may not be distributed in the United States, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, Belarus or Russia or other countries where the distribution of this invitation requires further action under the preceding sentence or is contrary to the rules of such country. Disputes due to the content of the Prospectus, this section of the Company’s website or related legal matters shall be settled in accordance with Danish law and in Danish courts.

I therefore certify that:

1. I am resident and physically present outside the United States, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, Belarus or Russia;

2. I am resident and physically present

   1. in Denmark or Sweden or

   2. outside Denmark or Sweden, the United States, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, Belarus or Russia and, in that case, I am authorized to access the information and documents on this website without being subject to any legal restriction and without any further action required by the Company; and

3. I have read, understand and agree to comply with all of the restrictions set forth above.